Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis

18 September 2019 - In this study, the investigators examined the characteristics of randomised controlled trials that supported approval of cancer ...

Read more →

For drug companies, there are real costs to unpopularity

10 September 2019 - A familiar headache for drug investors is likely to soon reappear. ...

Read more →

Drug prices keep rising amid political pressure, but not as fast

10 September 2019 - Prices for the majority of drugs in the U.S. have started to rise more slowly, likely ...

Read more →

Xeris Pharmaceuticals receives U.S. FDA approval for Gvoke (glucagon), the first ready-to-use stable liquid glucagon for severe hypoglycaemia

10 September 2019 - First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies. ...

Read more →

Why do post-marketing drug studies required by the FDA take so long?

10 September 2019 - Often times when a new drug is approved by the FDA, the agency requires more studies be ...

Read more →

Frontrunner to lead FDA, dogged by controversies, has developed knack for confronting them

10 September 2019 - Before he interviewed with President Trump last week to become FDA commissioner, Dr. Stephen Hahn had ...

Read more →

More Americans went without health insurance last year. It's the first increase in almost a decade.

10 September 2019 - The proportion of Americans without health insurance edged up in 2018 — the first increase in ...

Read more →

Greg Hunt's medical deals come back to bite him

11 September 2019 - Health minister Greg Hunt’s efforts to rein in growth in private health insurance premiums looks like ...

Read more →

Canada releases final amendments to patented medicines pricing regulations

9 September 2019 - On 9 August 2019 Health Canada announced the final amendments to the Patented Medicines Regulations. ...

Read more →

ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate

10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...

Read more →

Horizon Therapeutics announces the FDA has granted priority review of the teprotumumab biologics license application for the treatment of active thyroid eye disease

9 September 2019 - If approved, teprotumumab would be the first FDA approved medicine for this vision-threatening disease. ...

Read more →

ProQR receives fast track designation from FDA for QR-1123 for autosomal dominant retinitis pigmentosa

9 September 2019 - ProQR Therapeutics today announced that it received fast track designation from the FDA for QR-1123. ...

Read more →

FDA grants fast track status to Amplyx Pharmaceuticals for IV and oral formulations of fosmanogepix (APX001) for seven different indications

9 September 2019 -  -- Amplyx Pharmaceuticals announced today that the U.S. FDA has granted fast track designations for both ...

Read more →

Pelosi drug pricing plan would let government negotiate most costly medicines

9 September 2019 - The government would be allowed to directly negotiate the prices for some of the most expensive ...

Read more →

Reeling from scandal, Novartis vows to voluntarily release info on manipulated data in the future

9 September 2019 - Seeking to appease angry regulators, Novartis committed to notifying the FDA within five business days of ...

Read more →

Bernie Sanders went to Canada, and a dream of ‘Medicare for all’ flourished

9 September 2019 - The Vermont senator has staked his presidential campaign, and much of his political legacy, on transforming health ...

Read more →